Efg Asset Management (North America) Corp. Intellia Therapeutics, Inc. Transaction History

Efg Asset Management (North America) Corp.

$585 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 04, 2022	SELL	$38.49 - $76.21 $43,955 - $87,031	-1,142 Reduced 7.9%	13,316 $690,000
Q1 2022 Apr 26, 2022	BUY	$58.27 - $118.99 $842,467 - $1.72 Million	14,458 New	14,458 $1.05 Million

Others Institutions Holding NTLA

# of Institutions

316

Shares Held

91.7M

Call Options Held

442K

Put Options Held

880K

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

12.3M
Shares

$116 Million
2.39% of portfolio
Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$91.5 Million
0.0% of portfolio
Black Rock Inc. New York, NY

9.6M
Shares

$91.2 Million
0.0% of portfolio
State Street Corp Boston, MA

5.14M
Shares

$48.9 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.95M
Shares

$47 Million
3.75% of portfolio

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.

Account